KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Revenue (2019 - 2025)

Royalty Pharma's Revenue history spans 7 years, with the latest figure at $622.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 4.78% year-over-year to $622.0 million; the TTM value through Dec 2025 reached $2.4 billion, up 5.06%, while the annual FY2025 figure was $2.4 billion, 5.06% up from the prior year.
  • Revenue for Q4 2025 was $622.0 million at Royalty Pharma, up from $609.3 million in the prior quarter.
  • Across five years, Revenue topped out at $684.0 million in Q1 2023 and bottomed at $536.0 million in Q2 2022.
  • The 5-year median for Revenue is $570.6 million (2021), against an average of $576.2 million.
  • The largest annual shift saw Revenue increased 21.69% in 2023 before it decreased 16.96% in 2024.
  • A 5-year view of Revenue shows it stood at $575.7 million in 2021, then fell by 1.73% to $565.7 million in 2022, then rose by 5.36% to $596.1 million in 2023, then fell by 0.41% to $593.6 million in 2024, then grew by 4.78% to $622.0 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Revenue are $622.0 million (Q4 2025), $609.3 million (Q3 2025), and $578.7 million (Q2 2025).